Luminar to Provide Quarterly Update on November 13, 2025

ORLANDO, Fla.--(BUSINESS WIRE)-- Luminar (Nasdaq: LAZR), a leading global automotive technology company, today announced it will provide its quarterly update for the third quarter of 2025 following the close of the market on Thursday, November 13, 2025.

On November 13, 2025 at 4:00 p.m. EDT (1:00 p.m. PDT), the company will publish materials detailing its third quarter financials, which will be available on its Investor Relations website at https://investors.luminartech.com. At 5:00 p.m. EDT (2:00 p.m. PDT), the company will host a webcast consisting of prepared remarks and live Q&A. Shareholders are welcome to submit questions by emailing [email protected].

• What: Webcast featuring third quarter 2025 financials and live Q&A
• Date: Thursday, November 13, 2025
• Time: 5:00 p.m. EDT (2:00 p.m. PDT)
• Location: The webcast will be available live on Luminar’s Investor site at https://www.luminartech.com/quarterlyreview. A recording will be available following the conclusion of the webcast.

For additional information or to be added to our investor distribution list, please visit us at https://investors.luminartech.com/ir-resources/email-alerts.

About Luminar:

Luminar is a global technology company advancing safety, security and autonomy across automotive, commercial, and defense sectors. Its proprietary LiDAR hardware, software, semiconductor and photonics technologies have been developed in-house to meet the demanding performance and scalability requirements of applications spanning passenger vehicles, trucking, logistics, industrial, security, and more. With series production underway and commercial traction across industries, Luminar is uniquely positioned to deliver the next generation of advanced, mission-critical LiDAR and photonics solutions. For more information, please visit www.luminartech.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251013492268/en/

Contacts:
Investor Relations:
Yarden Amsalem
[email protected]

Media Relations:
Milin Mehta
[email protected]

Source: Luminar

You May Also Be Interested In

• Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
• Monad Price Prediction: AI Reviews Find 26 Code Issues as Remittix Plans a 20% Token Supply Reduction
• IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial